InsiderTrades.com logo
My #1 Pre IPO Trade for 2025 – NAME and TICKER
From Wyatt Investment Research   |   Ad
One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...
The Next SpaceX Pre-IPO
Michael J. Rider net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michael Rider Biography and Net Worth

General Counsel of ResMed

Michael Rider was appointed Global General Counsel and Secretary in July 2023. In his current role, Mike guides global legal strategy on a range of issues including intellectual property management; antitrust, anti-kickback, and other legal risks; corporate governance; acquisitions; privacy; and litigation. He previously served as ResMed’s senior vice president, deputy global general counsel, and legal business partner for ResMed’s Sleep & Respiratory Care team from July 2019 through June 2023, and before that as ResMed’s vice president and general counsel-Americas upon joining ResMed in June 2012.

Mike has nearly 40 years of legal experience. Prior to joining ResMed, he served as senior vice president, general counsel for Callaway Golf (NYSE: MODG), senior attorney for American Airlines (NASDAQ: AAL), and as a litigation associate at Gibson Dunn & Crutcher.

Mike graduated magna cum laude from the University of San Diego School of Law, served as executive editor of the San Diego Law Review, received its Distinguished Alumni Award in 2007, and currently serves on the USD School of Law Board of Visitors. He is also an executive committee member of the Corporate Directors Forum. Mike earned a Bachelor of Science in Pharmacy from the University of Arizona.

What is Michael J. Rider's net worth?

The estimated net worth of Michael J. Rider is at least $2.52 million as of November 1st, 2024. Mr. Rider owns 10,443 shares of ResMed stock worth more than $2,522,507 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Rider may own. Additionally, Mr. Rider receives an annual salary of $854,320.00 as General Counsel at ResMed. Learn More about Michael J. Rider's net worth.

How old is Michael J. Rider?

Mr. Rider is currently 66 years old. There are 5 older executives and no younger executives at ResMed. The oldest executive at ResMed is Dr. Peter C. Farrell A.M., B.E., BE, who is 82 years old. Learn More on Michael J. Rider's age.

What is Michael J. Rider's salary?

As the General Counsel of ResMed Inc., Mr. Rider earns $854,320.00 per year. There are 4 executives that earn more than Mr. Rider. The highest earning executive at ResMed is Mr. Michael J. Farrell BE, MBA, SM, CEO & Chairman, who commands a salary of $2,920,000.00 per year. Learn More on Michael J. Rider's salary.

How do I contact Michael J. Rider?

The corporate mailing address for Mr. Rider and other ResMed executives is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. ResMed can also be reached via phone at (858) 836-5000 and via email at [email protected]. Learn More on Michael J. Rider's contact information.

Has Michael J. Rider been buying or selling shares of ResMed?

Within the last three months, Michael J. Rider has sold $16,698.00 of ResMed stock. Most recently, Michael J. Rider sold 69 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $242.00, for a transaction totalling $16,698.00. Following the completion of the sale, the general counsel now directly owns 10,443 shares of the company's stock, valued at $2,527,206. Learn More on Michael J. Rider's trading history.

Who are ResMed's active insiders?

ResMed's insider roster includes Carol Burt (Director), Jan De Witte (Director), Robert Douglas (COO), Karen Drexler (Director), Michael Farrell (CEO), Peter Farrell (Director), Kaushik Ghoshal (Insider), James Hollingshead (Insider), Justin Leong (Insider), David Pendarvis (Insider), Michael Rider (General Counsel), Brett Sandercock (CFO), Rajwant Sodhi (Insider), and Ronald Taylor (Director). Learn More on ResMed's active insiders.

Are insiders buying or selling shares of ResMed?

In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 187,789 shares worth more than $41,061,987.20. The most recent insider tranaction occured on November, 12th when Director Witte Jan De sold 796 shares worth more than $198,052.76. Insiders at ResMed own 0.7% of the company. Learn More about insider trades at ResMed.

Information on this page was last updated on 11/12/2024.

Michael J. Rider Insider Trading History at ResMed

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2024Sell69$242.00$16,698.0010,443View SEC Filing Icon  
8/20/2024Sell882$231.00$203,742.0010,512View SEC Filing Icon  
3/4/2024Sell81$180.00$14,580.006,607View SEC Filing Icon  
3/1/2024Sell200$173.25$34,650.006,688View SEC Filing Icon  
11/1/2023Sell25$143.42$3,585.507,358View SEC Filing Icon  
10/2/2023Sell25$145.92$3,648.007,383View SEC Filing Icon  
8/1/2023Sell25$224.12$5,603.005,186View SEC Filing Icon  
7/3/2023Sell25$217.21$5,430.255,211View SEC Filing Icon  
See Full Table

Michael J. Rider Buying and Selling Activity at ResMed

This chart shows Michael J Rider's buying and selling at ResMed by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ResMed Company Overview

ResMed logo
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $241.30
Low: $241.30
High: $242.52

50 Day Range

MA: $242.10
Low: $231.43
High: $256.07

2 Week Range

Now: $241.30
Low: $151.95
High: $260.49

Volume

16,300 shs

Average Volume

1,039,343 shs

Market Capitalization

$35.42 billion

P/E Ratio

31.96

Dividend Yield

0.89%

Beta

0.69
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
From Darwin   |   Ad
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
👉 Click here to access your FREE report now!